spacer
home > ict > winter 2008 > cultural dimensions
PUBLICATIONS
International Clinical Trials

Cultural Dimensions

Clinical trials present a number of challenges for global pharmaceutical companies, says Gary Muddyman of Conversis, but additional issues are raised when the trials are extended to developing countries

The global clinical trials industry is currently estimated to be worth nearly $10 billion, and is expected to grow even further as concerns over safety and a highly competitive pharmaceutical market continue to drive demand for large clinical trials. In fact, according to a report from pharmaceutical R&D experts LeadDiscovery, global revenues from clinical trials have increased by almost 15 per cent in the last year alone (1).

Increasingly, developing countries are becoming a desirable location for much of this clinical research. To understand the reasons behind this change in policy, one simply needs to look at the complete drug development cycle. The entire process, which starts in the research labs and ends with a new drug being launched in the market, is not only time consuming but also extremely expensive.

As a result, global pharma companies based in developed countries are increasingly turning to developing countries and emerging economies around the world for their clinical trials, as reduced costs as well as easy availability of patients with varied diseases make developing regions a preferred destination for clinical research outsourcing.

WHAT DEVELOPING COUNTRIES DELIVER

According to the Offshoring Times, the cost of drug development is now estimated at $1 billion, and clinical trials on humans a critical phase in new drug development can sometimes account for 40 per cent of the total cost (2). Outsourcing clinical research to developing countries can allow global pharma companies to trim costs considerably. Clinical trials in India, for instance, can often cost 50 to 60 per cent less than the average cost in the US. Even more than cost, time is a crucial factor for pharma companies. When you consider that a patent only lasts 20 years, more than half of that time is often already gone by the time the drug is discovered, approved for clinical trials, tested and finally marketed.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Gary Muddyman is Managing Director and CEO of Conversis, a UK-based provider of globalisation, internationalisation, localisation and translation (GILT) services. Gary, together with a team that brings more than 60 years to the GILT market, founded Conversis with the idea of advancing the understanding and use of localisation and translation as a strategic business tool. Prior to joining Conversis, Gary served as Director of Operations for K International Plc, where he was responsible for all the development and implementation of business strategies. Prior to this, he spent 16 years working for HSBC Asset Finance UK Ltd, where he helped create the Metropolitan Collection Services, the debt management arm of HSBC. Gary received his MBA from Warwick University.
spacer
Gary Muddyman
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma and Memo Therapeutics AG sign a Development and Manufacturing Agreement

Vilnius, Lithuania, and Zurich, Switzerland June 25, 2020 Northway Biotechpharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and Swiss biotech company Memo Therapeutics AG have signed a Development and Manufacturing Agreement for a therapeutic antibody.
More info >>

White Papers

Running Smarter Trials With Data-Driven Monitoring

PAREXEL

Clinical monitoring remains one of the most important and most costly activities in the clinical research paradigm.  Monitoring provides the operational transparency required by investigators, sponsors, and regulators to make informed decisions about site performance, patient safety, and overall study progress. Yet unlike many clinical trial activities, which have been steadily transformed by technology, the monitoring function itself has changed little.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement